Silicon Valley is waking up to Longevity and senolytics

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Silicon Valley’s Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics.

Following-on from BioAge’s funding announcement, another biotech start-up has secured financing to progress the development of drugs that target the body’s aging processes. It appears that Silicon Valley is waking up to Longevity and senolytics.

Led by Khosla Ventures, Rubedo Life Sciences announced yesterday that it has closed a healthy $12m seed round.

Longevity.Technology: Along with $90m for BioAge led by Andreessen Horowitz and entrepreneur Elad Gil, and $15m for Elevian, there are strong indications that Silicon Valley investors are taking notice of Longevity.

Rubedo’s round included participation from Longevity Fund, Refactor Capital, AGE1 and Shanda, as well as additional investors.

Conditions and diseases associated with aging, such as dementia, cardiovascular disease and frailty, place a huge burden on healthcare, as well as negatively impacting lifespan and healthspan. Combating aging systematically by targeting senescence makes great Longevity sense, but drug development isn’t a fast process, or one that guarantees a win. Hopefully, Rubedo can progress their INDs through the pipeline to success.

Rubedo’s pipeline. Image credit: Rubedo Life Sciences, inc

Founded in 2018 by Julian Klein, Marco Quarta and Mark Gallop, the Silicon Valley start-up is developing therapies that selectively target and clear senescent cells from aged or pathological tissues. Senescent cells are cells that “forget” to die at the end of their lifespan, but remain metabolically active even though they have stopped replicating and growing.

Senescence is currently irreversible and senescent cells release cytokines and other toxins into the bloodstream, driving chronic inflammation, which plays a key role in disease progression, in fibrotic diseases such as IPF and tumour progression in cancer.

Rubedo’s proprietary ALEMBIC™ drug discovery platform, has generated a novel pipeline of therapeutic small molecule candidates that selectively target senescent cells, pro-inflammatory and pro-fibrotic cell populations that result from a variety of cellular stress and damage.

 


 

“This significant influx of financing will allow us to advance development of our pipeline, as we move our lead products toward clinical development …”

 


 

The funding will be used to advance Rubedo’s lead candidates in respiratory diseases with a significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). In addition, Rubedo hope to advance preclinical candidates in oncology, followed by neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into an investigational new drug (IND)-enabling studies in pulmonary diseases in 2021.

“We’re delighted to attract such a strong group of investors, led by Khosla Ventures. This significant influx of financing will allow us to advance development of our pipeline, as we move our lead products toward clinical development,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences.

“Rubedo has made remarkable progress and this seed investment will accelerate development of their clinical pipeline,” said Vinod Khosla, founder of Khosla Ventures. “Rubedo brings a skilled team and unique approach to developing innovative new therapies for chronic age-related diseases, and we are excited to build on this momentum.”

“We are impressed by the science, exceptional team, and the rate of progress at Rubedo under Marco’s leadership,” said Laura Deming, Managing Partner, Longevity Fund. “Our mission is to invest in world-class entrepreneurs developing therapeutic breakthroughs for age-related diseases and we’re incredibly excited to see Rubedo’s potential breakthrough treatments targeting fundamental processes in aging.”

Hungry for biotech? Check out our exclusive interview with Dr Kristen Fortney, co-founder and CEO of BioAge.

Image credit: Julian Prizont-Cado / Shutterstock.com

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Michael Antonov: longevity is all about tackling true unknowns

The Co-founder of Formic Ventures is using logic and innovation to drive the longevity sector forward. Michael Antonov is a serial entrepreneur and philanthropist who...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...